Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2287]

AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M...

Dr Vassiliki A. Papadimitrakopoulou - University of Texas MD Anderson Cancer...

AURA 3: Mechanisms of osimertinib resistance in patients with EGFR T790M advanced NSCLC ( Dr Vassiliki A. Papadimitrakopoulou - University of Texas MD Anderson Cancer Center, Houston, USA )

Comment on the TRIBE-2 study on first and second-line treatment for metastatic...

Dr Filippo Pietrantonio - ‎IRCCS Istituto Nazionale dei Tumori Foundation...

Comment on the TRIBE-2 study on first and second-line treatment for metastatic colorectal cancer ( Dr Filippo Pietrantonio - ‎IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy )

Pan-cancer assessment of BRCA1/2 genomic alterations by comprehensive genomic...

Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, Utah

Pan-cancer assessment of BRCA1/2 genomic alterations by comprehensive genomic profiling of tissue and circulating tumour DNA ( Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, Utah )

The standard of care and progress so far with PARP inhibitors for ovarian cancer

Dr Susana Banerjee - The Institute of Cancer Research, London, UK

The standard of care and progress so far with PARP inhibitors for ovarian cancer ( Dr Susana Banerjee - The Institute of Cancer Research, London, UK )

Updates from the EMBRACA trial for advanced breast cancer

Prof Hope Rugo - University of California, San Francisco, USA

Updates from the EMBRACA trial for advanced breast cancer ( Prof Hope Rugo - University of California, San Francisco, USA )

Tumour-infiltrating lymphocytes (TILs) as an independent prognostic factor for...

Dr Maria Vittoria Dieci - University of Padua, Padova, Italy

Tumour-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2 positive breast cancer ( Dr Maria Vittoria Dieci - University of Padua, Padova, Italy )

Key developments in prostate cancer

Prof Nicholas James, Prof Karim Fizazi, Prof Matthew Smith, Prof Álvaro Pinto...

Key developments in prostate cancer ( Prof Nicholas James, Prof Karim Fizazi, Prof Matthew Smith, Prof Álvaro Pinto and Dr Mark Beresford )

Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer

Dr Myriam Chalabi - Netherlands Cancer Institute, Amsterdam, Netherlands

Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer ( Dr Myriam Chalabi - Netherlands Cancer Institute, Amsterdam, Netherlands )

Updates in head and neck cancers

Prof Jean-Pascal Machiels - University Clinic Saint-Luc, Brussels, Belgium

Updates in head and neck cancers ( Prof Jean-Pascal Machiels - University Clinic Saint-Luc, Brussels, Belgium )

KEYNOTE022: Triplet therapy for BRAF melanoma

Prof Paolo Ascierto - Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale"...

KEYNOTE022: Triplet therapy for BRAF melanoma ( Prof Paolo Ascierto - Istituto Nazionale Tumori - IRCCS "Fondazione G.Pascale", Milan, Italy )

First-line pembrolizumab for recurrent/metastatic head and neck squamous cell...

Prof Barbara Burtness - Yale University School of Medicine and Yale Cancer...

First-line pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma ( Prof Barbara Burtness - Yale University School of Medicine and Yale Cancer Center New Haven, USA )

ESMO 2018: Melanoma highlights

Dr Teresa Amaral, Will Davies

ESMO 2018: Melanoma highlights ( Dr Teresa Amaral, Will Davies )

More from ecancer